VX- 222和INCIVEK+peg+rib可能治愈基因1型丙型肝炎12周少和不超过2

StephenW

Interim Data from Phase 2 Study of Combination Regimen Including VX-222  and INCIVEK Suggest Potential to Treat Genotype 1 Hepatitis C in as few  as 12 Weeks and No More Than 24  Weeks
                                  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 26, 2011 - Vertex Pharmaceuticals  Incorporated today announced interim results from ZENITH, an ongoing  Phase 2 study designed to assess  the safety, tolerability and efficacy  of multiple 12- and 24-week response-guided treatment regimens with  VX-222 (400 mg or 100 mg), its lead polymerase inhibitor in   development, in combination with INCIVEK (telaprevir) tablets,  pegylated-interferon and ribavirin in people with genotype 1 chronic  hepatitis C who were new to treatment.

临时从第2期联合用药的研究数据，包括VX- 222和INCIVEK提出潜在的治疗基因1型丙型肝炎12周少和不超过24周
马萨诸塞州剑桥 - （美国商业资讯） - 2011年07月26日 - Vertex制药公司今天公布中期业绩 - 从顶峰时期，正在进行的第二阶段的研究，旨在评估的安全性，耐受性和疗效的12多个和24周的反应制导与VX- 222（400毫克或100毫克），其发展导致INCIVEK（telaprevir）片剂，基因1型慢性丙型肝炎的人聚乙二醇干扰素和利巴韦林谁是新的治疗相结合，聚合酶抑制剂治疗方案。